Genmab (GMAB) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Genmab A/S, a leading biotechnology firm, announced that Baillie Gifford & Co now holds 4.99% of its shares, signaling a significant investment by the major shareholder. The company, renowned for its innovative antibody therapeutics and ambitious vision to revolutionize treatment for cancer and other serious diseases by 2030, emphasizes its strong international presence and a 25-year legacy of technological advancements in the biotech industry.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
